Artivion, Inc. (NYSE:AORT) Shares Acquired by American Century Companies Inc.

American Century Companies Inc. raised its stake in shares of Artivion, Inc. (NYSE:AORT) by 59.6% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 40,828 shares of the company’s stock after purchasing an additional 15,252 shares during the quarter. American Century Companies Inc.’s holdings in Artivion were worth $1,047,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Eagle Investment Management LLC increased its position in Artivion by 8.1% during the first quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock worth $12,066,000 after purchasing an additional 42,705 shares during the last quarter. Wasatch Advisors LP increased its position in Artivion by 108.8% during the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock worth $22,928,000 after purchasing an additional 564,549 shares during the last quarter. Vanguard Group Inc. increased its position in Artivion by 1.3% during the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after purchasing an additional 33,982 shares during the last quarter. Tidal Investments LLC acquired a new position in Artivion during the first quarter worth approximately $257,000. Finally, Allspring Global Investments Holdings LLC increased its position in Artivion by 291.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock worth $118,000 after purchasing an additional 4,154 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AORT. Oppenheimer boosted their price objective on shares of Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Lake Street Capital boosted their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Stifel Nicolaus boosted their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Artivion in a research note on Friday.

Insider Activity at Artivion

In related news, VP Matthew A. Getz sold 9,420 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $25.31, for a total value of $238,420.20. Following the sale, the vice president now directly owns 34,116 shares of the company’s stock, valued at $863,475.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Artivion news, VP Matthew A. Getz sold 9,420 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $25.31, for a total transaction of $238,420.20. Following the sale, the vice president now directly owns 34,116 shares of the company’s stock, valued at $863,475.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anthony B. Semedo sold 9,709 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total transaction of $242,627.91. Following the sale, the director now directly owns 34,159 shares in the company, valued at $853,633.41. The disclosure for this sale can be found here. Insiders have sold 24,679 shares of company stock valued at $626,518 over the last ninety days. Corporate insiders own 8.10% of the company’s stock.

Artivion Price Performance

Shares of AORT stock opened at $26.62 on Tuesday. The company has a market capitalization of $1.11 billion, a PE ratio of -113.71 and a beta of 1.74. The firm has a fifty day simple moving average of $25.84 and a 200-day simple moving average of $23.92. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. Artivion, Inc. has a twelve month low of $12.16 and a twelve month high of $29.24.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.04. The business had revenue of $98.02 million during the quarter, compared to the consensus estimate of $97.70 million. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. Equities research analysts anticipate that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.